<!DOCTYPE html>
<html>
  <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-79742963-1', 'auto');
  ga('send', 'pageview');

</script>

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘cancer’ in PubMed - pediatric oncology | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘cancer’ in PubMed - pediatric oncology" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-10-01T20:27:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html","headline":"What’s new for ‘cancer’ in PubMed - pediatric oncology","dateModified":"2011-10-01T20:27:00-03:00","datePublished":"2011-10-01T20:27:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘cancer’ in PubMed - pediatric oncology | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘cancer’ in PubMed - pediatric oncology" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-10-01T20:27:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Oct 01Search cancer &lt;div&gt;Limits:Randomized Controlled Trial, All Child: 0-18 years&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS.Division of Hematology-Oncology, Rainbow Babies &amp; Children’s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Blood. 2011 Jul 14;118(2):243-51. Epub 2011 May 11.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;AbstractChildren’s Cancer Group-1991 selected 2 components from the Children’s Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.PMID: 21562038 [PubMed - indexed for MEDLINE]Ful text: http://bit.ly/qeHiwx &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html","headline":"What’s new for ‘cancer’ in PubMed - pediatric oncology","dateModified":"2011-10-01T20:27:00-03:00","datePublished":"2011-10-01T20:27:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->


  <!--
  -->
 <link rel="alternate" type="application/rss+xml" title="" href="/ciencia-medica">

  <title>What's new for 'cancer' in PubMed - pediatric oncology</title>
  <meta name="description" content="This message contains My NCBI what's new results from the National Center for BiotechnologySender's message:  Sent on Saturday, 2011 Oct 01Search cancer Limi...">

  <!-- Google Fonts loaded here depending on setting in _data/options.yml true loads font, blank does not-->
  
    <link href='//fonts.googleapis.com/css?family=Lato:400,400italic' rel='stylesheet' type='text/css'>
  

  <!-- Load up MathJax script if needed ... specify in /_data/options.yml file-->
  
    <script type="text/javascript" src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  

  <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/tufte.css">
  <!-- <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/print.css" media="print"> -->

  <link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/10/01/whats-new-for-cancer-in-pubmed.html">
  <link rel="icon"
        type="image/png"
        href="/assets/img/badge.png">

  <link rel="alternate" type="application/rss+xml" title="Ciência médica" href="http://fhcflx.github.io/ciencia-medica/feed.xml" />

  <link rel="apple-touch-icon" sizes="180x180" href="/ciencia-medica/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/ciencia-medica/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/ciencia-medica/favicon-16x16.png">
  <link rel="manifest" href="/ciencia-medica/site.webmanifest">
  <link rel="mask-icon" href="/ciencia-medica/safari-pinned-tab.svg" color="#5bbad5">
  <link rel="shortcut icon" href="/ciencia-medica/favicon.ico">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/ciencia-medica/browserconfig.xml">
  <meta name="theme-color" content="#ffffff">

</head>

  <body>
    <!--- Hader and nav template site-wide -->
<header>
    <a class="site-title" href="/ciencia-medica/"></a>
    <nav class="group">
	<a href="/ciencia-medica/"><img class="badge" src="/ciencia-medica/assets/img/mybadge.png" alt="CH"></a>
        
	
		
		    
		      <a href="/ciencia-medica/index.html">Medical Science</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/all-posts/index.html">All</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/cancer2/index.html">Cancer</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/markers/index.html">Tags</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/about/index.html">About</a>
		    
	    
  	
        <!--<div class="trigger">
            
            
               
               <a class="page-link" href="/ciencia-medica/index.html">Medical Science</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/all-posts/index.html">All</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/cancer2/index.html">Cancer</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/markers/index.html">Tags</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/about/index.html">About</a>
               
            
            </div>-->
  </nav>
<div class="wrapper" style="text-align: right; line-height: 2em">
  
  

  
  
</div>
</header>

    <article class="group">
      <h1>What's new for 'cancer' in PubMed - pediatric oncology</h1>
<p class="subtitle">

1
Outubro
  
2011</p>





<ul class="tags">
  
    <li><a href="/ciencia-medica/marcadores#Cancer" class="tag">Cancer</a></li>
  
</ul>

This message contains My NCBI what's new results from the National Center for Biotechnology<br /><b>Sender's message: </b> <br />Sent on Saturday, 2011 Oct 01<br />Search <b>cancer</b> <br /><div>Limits:<b>Randomized Controlled Trial, All Child: 0-18 years</b></div><div><br /><div><table bgcolor="#CCCCCC"><tbody><tr><td align="center">PubMed Results</td></tr></tbody></table></div><br /><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10"></td><td valign="top"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21562038" ref="ordinalpos=5">Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">Matloub Y,  Bostrom BC,  Hunger SP,  Stork LC,  Angiolillo A,  Sather H,  La M,  Gastier-Foster JM,  Heerema NA,  Sailer S,  Buckley PJ,  Thomson B,  Cole C,  Nachman JB,  Reaman G,  Winick N,  Carroll WL,  Devidas M,  Gaynon PS.<br />Division of Hematology-Oncology, Rainbow Babies &amp; Children's  Hospital, Case Western Reserve University, Cleveland, OH 44106, USA.  yousif.matloub@uhhospitals.org </td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><b><span class="jrnl" title="Blood">Blood</span>.</b> 2011 Jul 14;118(2):243-51. Epub 2011 May 11.</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span style="font-size: small;"><b>Abstract</b></span><br />Children's Cancer Group-1991 selected 2 components from the Children's  Cancer Group studies shown to be effective in high-risk acute  lymphoblastic leukemia and examined them in children with National  Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia.  These were (1) vincristine and escalating IV methotrexate (MTX) without  leucovorin rescue during the interim maintenance (IM) phases and (2)  addition of a second delayed intensification (DI) phase. Eligible  patients (n = 2078) were randomly assigned to regimens containing either  oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV  MTX during IM phases, and regimens with either single DI or double DI.  Five-year event-free survival (EFS) and overall survival for patients on  the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2%  and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66).  Five-year EFS and overall survival for patients who received single DI  were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8%  for those who received double DI (P = .71, P = .12). No advantage was  found for a second DI; however, replacement of PO MTX, PO  mercaptopurine, vincristine, and dexamethasone during IM with  vincristine and escalating IV MTX improved EFS.<br />PMID: 21562038 [PubMed - indexed for MEDLINE]<br /><br />Ful text: <a href="http://bit.ly/qeHiwx">http://bit.ly/qeHiwx </a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td><br /></td></tr></tbody></table></div>


<article style="max-width: 90%;">
  <div id="disqus_thread"></div>
  <script>
    /**
     *  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
     *  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables
     */
    /*
    var disqus_config = function () {
        this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
        this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
    };
    */
      (function() {  // DON'T EDIT BELOW THIS LINE
          var d = document, s = d.createElement('script');
              s.src = '//pharmak-on.disqus.com/embed.js';

            s.setAttribute('data-timestamp', +new Date());
            (d.head || d.body).appendChild(s);
        })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript" rel="nofollow">comments powered by Disqus.</a></noscript>
</article>


    </article>
    <span class="print-footer">What's new for 'cancer' in PubMed - pediatric oncology - October 1, 2011 - fhcflx</span>
    <footer>
  <hr class="slender">
  <ul class="footer-links">
    <li><a href="mailto:fhcflx@outlook.com"><span class="icon-mail"></span></a></li>
    
      <li>
        <a href="//www.twitter.com/fhcflx"><span class="icon-twitter"></span></a>
      </li>
    
      <li>
        <a href="//plus.google.com/+FranciscoHCFelix"><span class="icon-googleplus"></span></a>
      </li>
    
      <li>
        <a href="//github.com/fhcflx/ciencia-medica"><span class="icon-github"></span></a>
      </li>
    
      <li>
        <a href="//www.flickr.com/photos/fhcflx"><span class="icon-flickr"></span></a>
      </li>
    
      <li>
        <a href=""><span class="icon-feed"></span></a>
      </li>
    
    <li><a href=https://travis-ci.org/fhcflx/ciencia-medica ><img alt='travis-ci build' src=https://img.shields.io/travis/fhcflx/ciencia-medica.svg?colorA=a00000&colorB=a00000></a></li>
  </ul>
<div class="credits">
<span>&copy; 2019 &nbsp;&nbsp;FHCFLX</span></br> <br>
<span>Este sítio foi criado com o <a href="//github.com/clayh53/tufte-jekyll">tema Tufte para Ciência médica </a> no <a href="//jekyllrb.com">Jekyll</a>.</span>
</div>
</footer>

  </body>
</html>
